Moderna
MRNAModerna is a biotechnology company that pioneered a proprietary messenger RNA (mRNA) platform to develop a new class of medicines.
Earnings
Next report
Nov 5, 2026 (in 2 months)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Moderna is a biotechnology company that pioneered a proprietary messenger RNA (mRNA) platform to develop a new class of medicines. The company's technology functions as 'software' for life, instructing cellular machinery to produce specific proteins to prevent or treat infectious diseases, immuno-oncology, and rare genetic disorders. Their primary value proposition lies in a rapid, scalable manufacturing network and a versatile platform that can address multiple therapeutic areas using the same underlying science.
Moderna is a dominant leader in the mRNA space with a first-mover advantage in mRNA vaccines and a highly integrated global manufacturing footprint.
FAQ
- What is Moderna's market cap?
- Moderna (MRNA) has a market capitalization of $59.7B and trades on NASDAQ.
- What is Moderna's revenue and profitability?
- Moderna generated $2.2B in trailing twelve-month revenue with a net loss of $3.2B, representing a net margin of -141.4%. Gross margin stands at 23.4%, with free cash flow of -$3.1B. These figures are based on the Q2 2026 filing.
- Who are Moderna's competitors?
- Moderna's key competitors include Pfizer, GeoVax Labs, Inc. New, Arcturus Therapeutics Holdings Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Moderna partner with?
- Moderna's notable partners include Merck & Co., Recordati, Pfizer, and others.
- Where is Moderna headquartered?
- Moderna is headquartered in United States of America and employs approximately 5,600 people. It has been publicly traded since 2018.
